Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 1.00 |
| ▸ | CNR2 | P34972 | 6/20 | 1.00 |
| ▸ | PSMB11 | A5LHX3 | 3/20 | 1.00 |
| ▸ | PSMA7 | O14818 | 3/20 | 1.00 |
| ▸ | PSMB1 | P20618 | 3/20 | 1.00 |
| ▸ | PSMA1 | P25786 | 3/20 | 1.00 |
| ▸ | PSMA2 | P25787 | 3/20 | 1.00 |
| ▸ | PSMA3 | P25788 | 3/20 | 1.00 |
| ▸ | PSMA4 | P25789 | 3/20 | 1.00 |
| ▸ | PSMB8 | P28062 | 3/20 | 1.00 |
| ▸ | PSMB9 | P28065 | 3/20 | 1.00 |
| ▸ | PSMA5 | P28066 | 3/20 | 1.00 |
| ▸ | PSMB4 | P28070 | 3/20 | 1.00 |
| ▸ | PSMB6 | P28072 | 3/20 | 1.00 |
| ▸ | PSMB5 | P28074 | 3/20 | 1.00 |
| ▸ | PSMB10 | P40306 | 3/20 | 1.00 |
| ▸ | PSMB3 | P49720 | 3/20 | 1.00 |
| ▸ | PSMB2 | P49721 | 3/20 | 1.00 |
| ▸ | PSMA6 | P60900 | 3/20 | 1.00 |
| ▸ | PSMA8 | Q8TAA3 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157919 | 1.00 | CNR1 (1.00) | CNR1CNR2PSMB11PSMA7PSMB1 | |
| SCHEMBL6705877 | 1.00 | CNR1 (1.00) | CNR1CNR2PSMB11PSMA7PSMB1 | |
| SCHEMBL8390708 | 0.96 | PSMB11 (0.94) | CNR1CNR2PSMB11PSMA7PSMB1 | |
| SCHEMBL8389682 | 0.93 | PSMB11 (1.00) | CNR1CNR2PSMB11PSMA7PSMB1 | |
| SCHEMBL8589573 | 0.93 | PSMB11 (1.00) | CNR1CNR2PSMB11PSMA7PSMB1 | |
| SCHEMBL8589576 | 0.93 | PSMB11 (1.00) | CNR1CNR2PSMB11PSMA7PSMB1 | |
| SCHEMBL18240151 | 0.87 | SOAT2 (0.86) | CNR1CNR2PSMB11PSMA7PSMB1 | |
| SCHEMBL18240149 | 0.87 | SOAT2 (0.86) | CNR1CNR2PSMB11PSMA7PSMB1 | |
| SCHEMBL23021636 | 0.86 | CNR1 (0.76) | CNR1CNR2PSMB11PSMA7PSMB1 | |
| SCHEMBL8622052 | 0.85 | PSMB11 (0.85) | CNR1CNR2PSMB11PSMA7PSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250009655-A1 | BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE | Natural Extraction Systems, LLC | 2025-01-09 | — | — | US | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2023064318-A1 | BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE | Natural Extraction Systems, LLC (US) | 2023-04-20 | — | — | WO | claimed |
| EP-1636335-B1 | COMPOSITIONS AND METHODS FOR INHIBITING AN ISOFORM OF HUMAN MANGANESE SUPEROXIDE DISMUTASE | MITO TEK LLC (US) | 2012-07-11 | — | — | EP | claimed |
| WO-2001001980-A9 | METHODS FOR THE AMELIORATION OF NEUROPSYCHIATRIC DISORDERS BY INHIBITING THE INACTIVATING TRANSPORT OF ENDOGENOUS CANNABINOID SUBSTANCES | UNIV CALIFORNIA (US) | 2002-08-29 | — | — | WO | claimed |
| WO-2001001980-A1 | METHODS FOR THE AMELIORATION OF NEUROPSYCHIATRIC DISORDERS BY INHIBITING THE INACTIVATING TRANSPORT OF ENDOGENOUS CANNABINOID SUBSTANCES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-01-11 | — | — | WO | claimed |
| US-12390418-B2 | Biphasic compositions comprising one or both of carbonate and phosphate | Natural Extraction Systems, LLC (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250009655-A1 | BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE | Natural Extraction Systems, LLC | 2025-01-09 | — | — | US | disclosed |
| CN-115919824-B | Application of AM404 in preparing medicament for preventing and treating myocardial ischemia reperfusion injury | 首都医科大学附属北京朝阳医院 | 2023-07-11 | — | — | CN | disclosed |
| US-10414721-B1 | Inhibitor of endocannabinoid cellular reuptake | UNIVERSITY OF BERN (CH) | 2019-09-17 | — | — | US | disclosed |
| US-20160169914-A1 | KINETICS BIOMARKERS FOR NEURODEGENERATION | KINEMED, INC. (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016044665-A1 | KINETICS BIOMARKERS FOR NEURODEGENERATION | KINEMED, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| EP-2972329-A2 | BIOMARKERS | Kinemed, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-1294411-A1 | A NOVEL TREATMENT FOR COUGH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001001980-A9 | METHODS FOR THE AMELIORATION OF NEUROPSYCHIATRIC DISORDERS BY INHIBITING THE INACTIVATING TRANSPORT OF ENDOGENOUS CANNABINOID SUBSTANCES | UNIV CALIFORNIA (US) | 2002-08-29 | — | — | WO | disclosed |
| US-20020035150-A1 | Novel treatment for cough | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2002-03-21 | — | — | US | disclosed |
| US-20020019444-A1 | Anandamide and structurally related lipids as vanilloid receptor modulators | HOGESTATT EDWARD (SE) | 2002-02-14 | — | — | US | disclosed |
| WO-2001089589-A1 | A NOVEL TREATMENT FOR COUGH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001085158-A2 | ANANDAMIDE AND STRUCTURALLY RELATED LIPIDS AS VANILLOID RECEPTOR MODULATORS | FORSKARPATENT I SYD AB (SE) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001001980-A1 | METHODS FOR THE AMELIORATION OF NEUROPSYCHIATRIC DISORDERS BY INHIBITING THE INACTIVATING TRANSPORT OF ENDOGENOUS CANNABINOID SUBSTANCES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019444-A1 | Anandamide and structurally related lipids as vanilloid receptor modulators | TRPV1, CNR2, CNR1 | CNR1 3/4885CNR2 2/4885PSMB11 2928/4885 |
| US-10414721-B1 | Inhibitor of endocannabinoid cellular reuptake | CNR1, CNR2, SLC18A2 | CNR1 1/4885CNR2 2/4885PSMB11 3250/4885 |
| US-20020035150-A1 | Novel treatment for cough | CNR1, CNR2, TRPV1 | CNR1 1/4885CNR2 2/4885PSMB11 2828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.